European Journal of Epidemiology

, Volume 29, Issue 6, pp 383–390 | Cite as

Personalised medicine, disease prevention, and the inverse care law: more harm than benefit?

COMMENTARY

Keywords

Personalised medicine Inverse care law Inverse benefit law Preventive medicine GWAS Omic technologies Pharmacogenomics 

References

  1. 1.
    Hart JT. The inverse care law. Lancet. 1971;1(7696):405–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011;8:184–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res. 2004;3:179–96.PubMedCrossRefGoogle Scholar
  4. 4.
    Khoury MJ, Gwinn ML, Glasgow RE, et al. A population approach to precision medicine. Am J Prev Med. 2012;42:639–45.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Offit K. Personalized medicine: new genomics, old lessons. Hum Genet. 2011;130:3–14.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    National Cancer Institute. NCI dictionary of cancer terms. http://www.cancer.gov/dictionary/?CdrID=561717. Accessed 20 March 2013.
  7. 7.
    Melzer D, Zimmern R. Genetics and medicalisation. BMJ. 2002;324:863–4.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Tutton R. Personalizing medicine: futures present and past. Soc Sci Med. 2012;75:1721–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Kitsios GD, Kent DM. Personalised medicine: not just in our genes. BMJ. 2012;344:e2161. doi:10.1136/bmj.e2161.PubMedCrossRefGoogle Scholar
  10. 10.
    Turkheimer E. Genome wide association studies of behavior are social science. Boston Studies in the Philosophy of Science. 2012;282:43–64.CrossRefGoogle Scholar
  11. 11.
    Juengst E, Flatt MA, Settersten RA. Personalized genomic medicine and the rhetoric of empowerment. Hastings Cent Rep. 2012;42:34–40.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Corrigan OP. Personalized medicine in a consumer age. Curr Pharmacogenomics Person Med. 2011;9:168–76.CrossRefGoogle Scholar
  13. 13.
    Squassina A, Manchia M, Manolopoulos VG, et al. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics. 2010;11:1149–67.PubMedCrossRefGoogle Scholar
  14. 14.
    Mallal S, Phillips E, Carosi G, et al. HLA-B* 5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–79.PubMedCrossRefGoogle Scholar
  15. 15.
    Manolio TA., Chisholm RL, Ozenberger B, et al. Implementing genomic medicine in the clinic: the future is here. Genet Med. 2013. doi:10.1038/gim.2012.157.
  16. 16.
    Shah RR, Shah DR. Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol. 2012;74:698–721.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Pashayan N, Pharoah P. Population-based screening in the era of genomics. Per Med. 2012;9:451–5.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Burke W, Trinidad SB, Press NA. Essential elements of personalized medicine. Semin Urol Oncol. 2014;32:193–7.CrossRefGoogle Scholar
  19. 19.
    Manolio TA, Weis BK, Cowie CC. New models for large prospective studies: is there a better way? Am J Epidemiol. 2012;175:859–66.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Smith GD. Epidemiology, epigenetics and the ‘gloomy prospect’: embracing randomness in population health research and practice. Int J Epidemiol. 2011;40:537–62.PubMedCrossRefGoogle Scholar
  21. 21.
    Wagner A. The role of randomness in Darwinian evolution. Philos Sci. 2012;79:95–119.CrossRefGoogle Scholar
  22. 22.
    MacMahon S. Blood pressure and the risk of cardiovascular disease. N Engl J Med. 2000;342:50–2.PubMedCrossRefGoogle Scholar
  23. 23.
    Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.PubMedCrossRefGoogle Scholar
  24. 24.
    Smolen JS, Aletaha D. Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis. 2013;72:3–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Ioannidis JPA. Genetics, personalized medicine, and clinical epidemiology: expectations, validity, and reality in omics. J Clin Epidemiol. 2010;63:945–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Adams SD, Evans JP, Aylsworth AS. Direct-to-consumer genomic testing offers little clinical utility but appears to cause minimal harm. NC Med J. 2013;74:494–9.Google Scholar
  27. 27.
    Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363:301–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Alpert JS, Chen QM. Has the genomic revolution failed? Clin Cardiol. 2012;35:178–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Khoury MJ, Janssens ACJ, Ransohoff DF. How can polygenic inheritance be used in population screening for common diseases? Genet Med. 2013;15:437–43.PubMedCrossRefGoogle Scholar
  30. 30.
    Gage M, Wattendorf D, Henry LR. Translational advances regarding hereditary breast cancer syndromes. J Surg Oncol. 2012;105:444–51.PubMedCrossRefGoogle Scholar
  31. 31.
    Burke W, Tarini B, Press NA, Evans JP. Genetic screening. Epidemiol Rev. 2011;33:148–64.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Ioannidis JP, Tzoulaki I. Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. Circ Res. 2012;110:658–62.PubMedCrossRefGoogle Scholar
  33. 33.
    Patel JN, McLeod HL, Innocenti F. Implications of genome-wide association studies in cancer therapeutics. Br J Clin Pharmacol. 2013;76:370–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Lyssenko V, Laakso M. Genetic screening for the risk of Type 2 diabetes worthless or valuable? Diabetes Care. 2013;36(Suppl 2):S120–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Beekman M, Nederstigt C, Suchiman HED, et al. Genome-wide association study (GWAS)-identified disease risk alleles do not compromise human longevity. Proc Natl Acad Sci. 2012;107:18046–9.CrossRefGoogle Scholar
  36. 36.
    McBride CM, Bowen D, Brody LC, et al. Future health applications of genomics: priorities for communication, behavioral, and social sciences research. Am J Prev Med. 2010;38:556–65.PubMedCrossRefGoogle Scholar
  37. 37.
    Grant RW, O’Brien KE, Waxler JL, et al. Personalized genetic risk counseling to motivate diabetes prevention: a randomized trial. Diabetes Care. 2013;36:13–9.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. BMJ. 2012;344:e3502. doi:10.1136/bmj.e3502.PubMedCrossRefGoogle Scholar
  39. 39.
    Hoffman KE. Management of older men with clinically localized prostate cancer: the significance of advanced age and comorbidity. Semin Radiat Oncol. 2012;22:284–94.PubMedCrossRefGoogle Scholar
  40. 40.
    Dubben HH. Trials of prostate-cancer screening are not worthwhile. Lancet Oncol. 2009;10:294–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Carrera S, Beaumont J. Income and wealth. Soc Trends 2010; 41: ISSN 2040–1620. Newport, UK: Office for National Statistics. www.statistics.gov.uk/. Accessed 20 March 2013.
  42. 42.
    United Nations Development Programme. Human development report 2010. 20th Anniversary Edition. The real wealth of nations: pathways to human development. New York, NY: UNDP; 2010.Google Scholar
  43. 43.
    Wang H, Dwyer-Lindgren L, Lofgren KT, et al. Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2071–94.PubMedCrossRefGoogle Scholar
  44. 44.
    Brody H, Light DW. The inverse benefit law: how drug marketing undermines patient safety and public health. Am J Public Health. 2011;101:399–404.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Kolber MR, Korownyk C. An aspirin a day? Aspirin use across a spectrum of risk: cardiovascular disease, cancers and bleeds. Expert Opin Pharmacother. 2014;15:153–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Redberg RF, Katz MH. Healthy men should not take statins. JAMA. 2012;307:1491–2.PubMedCrossRefGoogle Scholar
  47. 47.
    Maron DJ, Ting HH. In mildly symptomatic patients, an invasive strategy with catheterization and revascularization should not be routinely undertaken. Circulation. 2013;6:114–21.PubMedGoogle Scholar
  48. 48.
    Abbott AL, Adelman MA, Alexandrov AV, et al. Why calls for more routine carotid stenting are currently inappropriate: an international, multispecialty, expert review and position statement. Stroke. 2013;44:1186–90.PubMedCrossRefGoogle Scholar
  49. 49.
    Eriksen EF, Díez-Pérez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone. 2014;58:126–35.PubMedCrossRefGoogle Scholar
  50. 50.
    Alonso-Coello P, García-Franco AL, Guyatt G, Moynihan R. Drugs for pre-osteoporosis: prevention or disease mongering? BMJ. 2008;336:126–9.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Caulfield T, Chandrasekharan S, Joly Y, Cook-Deegan R. Harm, hype and evidence: ELSI research and policy guidance. Genome Med. 2013;5:21–21.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Williams SJ, Martin P, Gabe J. The pharmaceuticalisation of society? A framework for analysis. Sociol Health. 2011;33:710–25.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.Reykjavík UniversityReykjavíkIceland
  2. 2.National University of IrelandGalwayIreland

Personalised recommendations